Tissue damage by self-antigen--specific T lymphocytes causes autoimmune diseases such as type 1 diabetes. In these disorders, defective central tolerance ([@bib30]) and peripheral regulation ([@bib24]) lead to initiation of autoantigen-specific responses in a cascade of molecular and cellular interactions between antigen-presenting cells and T lymphocytes. During the effector phase, activated CD4^+^ and CD8^+^ T~eff~ cells migrate to target tissues to inflict damage. The immune destruction at this phase can be suppressed by CD4^+^Foxp3^+^ T~reg~ cells ([@bib24]), as demonstrated in models of autoimmune diabetes ([@bib7]; [@bib14]). Extensive studies have contributed to the understanding of immune responses at the induction phase in lymphoid organs; however, the behavior of immune cells in nonlymphoid target tissues remains murky.

High-resolution imaging of live cells in lymphoid organs has elucidated key features of cellular dynamics during the initiation phase of immune responses ([@bib16]). A major gap of knowledge remains, however, in understanding immune cell action and interaction in nonlymphoid target tissues, except in some infection models. In particular, noninvasive real-time evidence of how pathogenic immune cells at the effector phase engage target cells, how immune damage is controlled, and how target tissue cells respond remains scanty. This is largely a result of technical limitations that make most target tissues inaccessible to noninvasive visualization at cellular levels. Researchers often have to resort to surgical exposure of tissue or invasive insertion of a probe during imaging. Surgical wounds, however, create a two-pronged limitation on imaging analyses. First, they make longitudinal analyses difficult, if possible. Second, the acute surgical wound leads to immediate release of an array of inflammatory cytokines that may confound the interpretation of immune cell behavior uncovered in a traumatic setting. As a result, key events in the cascade of CD4^+^ and CD8^+^ T cell--mediated immune damage or protection in target tissue remain poorly delineated.

A recently established imaging platform, intravital microscopy of pancreatic islets engrafted in the anterior chamber of the mouse eye (ACE), facilitated high-resolution visualization of immune cells noninvasively and longitudinally ([@bib49],[@bib50]; [@bib1]). In this study, we take advantage of this imaging platform, along with a series of reductionist animal models. We established models of effective immune responses in the ACE imaging site versus the native pancreas, in terms of equivalent kinetics of tissue damage and regulatory T (T~reg~) cell--mediated protection. Using this noninvasive imaging approach, we studied in real time how self-antigen--specific T cells interacted with target tissue cells in vivo. We depicted the behavior of three major T cell lineages (CD4^+^ effector T \[T~eff~\] cells, CD4^+^ T~reg~ cells, and CD8^+^ T~eff~ cells), analyzed the regulatory effect of CTLA4 on their behavior, and examined tissue responses in destructive settings.

RESULTS
=======

Noninvasive imaging of T cells in ACE without hindrance by the putative immunoprivilege
---------------------------------------------------------------------------------------

To study CD4^+^ T cell responses in target tissue, we used CD4^+^ T~eff~ and T~reg~ cells from the NOD.BDC2.5 TCR transgenic mice ([@bib25]), with a specificity against a natural antigen in the pancreatic islet β cells, chromogranin A ([@bib51]). ACE offers the technical advantage of noninvasive access and high resolution in vivo imaging, but studies using ACE could be complicated by a status of immune privilege attributed to this compartment of the eye ([@bib3]). To test whether this impacts on the immune responses of antigen-specific T cells in the islet grafts in ACE, we compared the frequency of immune damage by BDC2.5 CD4^+^ T~eff~ cells against β cells in the ACE graft and that in the native pancreas. Donor pancreatic islets were injected into ACE through the cornea ([@bib49],[@bib50]; [@bib1]) at least 2 wk before T cell transfer, to ensure stable engraftment of the islets and complete healing of the minor injection wound.

Although previous studies in other settings showed that immune cells in ACE could be impacted by the eye-associated immunoprivilege ([@bib3]), in our model we found that the β cell--specific CD4^+^ BDC2.5 T~eff~ cells destroyed the islets in the pancreas and the islet grafts in ACE at a similar tempo. Importantly, the protective T~reg~ cells acted with a similar efficacy (∼50%) in controlling T~eff~ cell damage in ACE and in the endogenous pancreas ([Fig. 1, A--D](#fig1){ref-type="fig"}). Antigen-specific T~reg~ cells have been shown to be potent suppressors in several autoimmune settings, including models of type 1 diabetes ([@bib59]; [@bib48]). The main reason that only 50% of mice were protected in our experiments was likely because of the potency of the antigen-specific T~eff~ cells, which were purified BDC2.5 CD4^+^CD25^−^Foxp3^−^ cells. Nonetheless, these results are consistent with a previous study that found rejection of fully MHC-mismatched islets in ACE occurred similarly to that in a conventional extra-pancreatic implant site, the kidney sub-capsular space ([@bib1]). Therefore, the overall kinetics of immune destruction and protection of engrafted islet tissue in ACE was comparable to that in the native pancreas, and thus the islet grafts in ACE could serve as a surrogate in noninvasive and longitudinal imaging studies of basic T cell biology at the effector phase in the nonlymphoid target tissue.

![**Noninvasive imaging in ACE was not complicated by the putative immunoprivilege and enabled visualization of the interaction between CD4^+^ T~eff~ cells and their target cells.** (A--D) The efficacies of β cell antigen--specific CD4^+^ T~eff~ and T~reg~ cells in the endogenous pancreatic islet were compared with that of islet grafts in the anterior chamber of the eye (ACE). (A) For immune responses in native pancreata, NOD.SCID mice were injected with either BDC2.5 T~eff~ cells or T~reg~--T~eff~ mixture. Damage to pancreatic islets was monitored by reading blood glucose (BG) levels. Animals with consecutive readings of BG \> 250 mg/deciliter were considered diabetic, or failed T~reg~ cell protection if T~reg~ cells were co-transferred with T~eff~ cells. For immune responses in ACE grafts, NOD.SCID mice were rendered diabetic through streptozotocin destruction of pancreatic β cells, and then transplanted with pancreatic islets from allogeneic (B6) or syngeneic (NOD.SCID) donors into ACE. After stable engraftment (\>2 wk after transplantation), CD4^+^ T~eff~ cells alone (B) or T~reg~--T~eff~ mixture (C) was injected into the graft-bearing mice. Graft damage was monitored by BG readings. (D) Summary of results in A--C. The cumulative incidence of diabetes was calculated for the groups of animals (*n* = 4--26; 2--3 experiments) presented individually in A--C. (E) 3D rendering of in vivo fluorescence micrographs for apoptotic signal Annexin V in areas of CD4^+^ BDC2.5 T~eff~ cells engaging in direct contact with β cell targets. The results represent two experiments with a total of 4 mice analyzed with snapshot imaging of 1--3 islets per animal. Bar, 100 µm. See [Video 1](http://www.jem.org/cgi/content/full/jem.20130785/DC1){#supp1}.](JEM_20130785_Fig1){#fig1}

Direct contact between antigen-specific CD4^+^ T~eff~ cells and their target cells
----------------------------------------------------------------------------------

CD4^+^ T cells are categorized into several helper and regulatory subsets. Their function as killers has also been shown ([@bib19]). The in vivo capacity of CD4^+^ T~eff~ cells killing target β cells was shown in [Fig. 1 (A--D)](#fig1){ref-type="fig"}. How CD4^+^ T cells kill remains to be fully examined. Most target tissues do not express MHC class II molecules, which are necessary for antigen-specific, cognate interaction with CD4^+^ T cells. To study tissue destruction by antigen-specific CD4^+^ T~eff~ cells, pancreatic islets tagged with cyan fluorescence proteins (CFP; [@bib21]) were grafted in ACE. CD4^+^Foxp3^−^ BDC2.5 T~eff~ cells marked with green fluorescence proteins (GFP) were injected into the intraocular graft-bearing animals. The GFP^+^CD4^+^ T~eff~ cells appeared in the islet grafts and engaged in direct contact with their target β cells. We then used Annexin V in situ cytolabeling to visualize apoptosis of β cells, by injecting allophycocyanin (APC)-conjugated Annexin V into ACE. The use of this in vivo assay for β cell apoptosis was described in detail in previous works ([@bib49],[@bib50]). Apoptosis signals were present in either the contact zone between T~eff~ cells and target islet cells, or on the target islet cells with T~eff~ cells in the vicinity but not in direct contact ([Fig. 1 E](#fig1){ref-type="fig"} and [Video 1](http://www.jem.org/cgi/content/full/jem.20130785/DC1){#supp2}). We also examined the involvement of myeloid cells at the inflammatory site, by in situ immunocytolabeling ([@bib1]) with anti-CD11b antibodies. We could not detect CD11b^+^ cells in most of the areas wherein T~eff~ cells interacted with target β cells. A low frequency of CD11b^+^ cells were found but usually in the periphery of damaged grafts. Importantly, T~reg~ cells colocalized in the protected clusters of β cells that persisted amid areas of immune damage ([Fig. 2, A--C](#fig2){ref-type="fig"}). Overall, the majority of Annexin V signals associated with β cells rather than T~eff~ cells and the amount of the apoptotic signals on β cells positively correlated with the number of T~eff~ cells at the inflammatory site ([Fig. 2, D and E](#fig2){ref-type="fig"}). The exact molecular cause of the immunopathology by the CD4^+^ T~eff~ cells remains unclear. IFN-γ and IL-17A could be detected by flow cytometry in substantial proportions of the CD4^+^ T~eff~ cells in the draining cervical lymph nodes of the eyes (14 ± 2 and 6 ± 1%, respectively; mean ± SEM; *n* = 8 mice). However, further studies are needed to determine whether these or other cytokines have a pathogenic role. The imaging data suggest that, although not exclusive, direct contact may be involved in CD4^+^ T~eff~ cell killing of target cells, even in the absence of CD8^+^ T~eff~ cells. The contact-dependent mode is a hallmark of cytotoxicity by CD8^+^ T~eff~ cells.

![**Direct contact between CD4^+^ T~eff~ cells, target tissue cells and T~reg~ cells, with or without close proximity to myeloid cells.** Fluorescence confocal micrographs (z-stacks) acquired within intraocular islet grafts in NOD.SCID recipients in vivo. The mice were reconstituted with CFP-labeled CD4^+^ BDC2.5 T~eff~ cells (blue) and GFP-labeled T~reg~ cells (green), and later injected directly into ACE with BV605-conjugated anti-CD11b antibodies to label a broad subset of myeloid cells (yellow) and APC-conjugated Annexin V (red) to detect apoptotic cells in situ. The target β cells were visualized by laser backscatter (gray). (A and B) The Annexin V apoptotic signals were detected in areas of CD4^+^BDC2.5T~eff~ cells engaging target β cells, in the absence (A) or in the presence (B) of CD11b^+^ myeloid cells. (C) T~reg~ cells colocalized in the protected cluster of β cells, which persisted amid rejected areas as long as T~reg~ cells existed. (D) The Annexin V signals on either β cells or T cells were measured as overlap between Annexin V stain volume and that of either β or T cells, normalized to total volume (β and T cells; mean ± SEM). (E) Linear regression analyses correlating β cell apoptosis (Annexin V signal) with the number of intra-graft T cells (*n* = 10 islet grafts in 4 mice). \*\*, P \< 0.01. Bars, 50 µm. See [Video 1](http://www.jem.org/cgi/content/full/jem.20130785/DC1){#supp3}.](JEM_20130785_Fig2){#fig2}

Direct engagement between CD8^+^ T~eff~ cells and target cells: bystander β cells were not subject to killing but grew at the interface of immune damage
--------------------------------------------------------------------------------------------------------------------------------------------------------

We next studied noninvasive CD8^+^ T~eff~ cell activity in target tissue, by using CD8^+^ OT1 transgenic T cells ([@bib22]), which are specific toward a model antigen, ovalbumin. Donor islets from both the RIP-mOVA transgenic mice ([@bib26]), which express ovalbumin in β cells, and the MIP-CFP mice, which lack ovalbumin but have CFP-labeled β cells ([@bib21]), were grafted together in ACE of C57BL/6 (B6) animals. We selected transplanted animals that carried at least one pair of conjoined mOVA^+^CFP^−^ and mOVA^−^CFP^+^ grafts like Siamese twins, and transferred them with antigen-activated CD8^+^GFP^+^ OT1 T~eff~ cells. This was done to examine antigen-specific killing versus bystander tissue destruction ([@bib60]). The CD8^+^ OT1 T~eff~ cells selectively destroyed β cells carrying the specific antigen ([Fig. 3, A--C](#fig3){ref-type="fig"}).

![**CD8^+^ T~eff~ cells damaged antigen-specific target cells but not bystander cells.** (A) Longitudinal fluorescence confocal micrographs (z stacks shown as maximum projection) of islet grafts in ACE, acquired noninvasively in vivo. Visualized were infiltration and damage by OVA-specific GFP-labeled CD8^+^OT1 T~eff~ cells in OVA^+^CFP^−^ islet grafts (gray) versus bystander OVA^−^CFP^+^ islets (blue). Data represent a total of 6 pairs of antigen-specific OVA^+^CFP^−^ and nonspecific OVA^−^CFP^+^ islets conjoined like Siamese twins (left), total 6 separated OVA^−^CFP^+^ islets (right) in the same ACE environment but not conjoined with OVA^+^CFP^−^ grafts, and total 6 separated OVA^+^CFP^−^ islet grafts, from 5 different mice in three experiments. (B) Changes in relative islet mass (volume; mean ± SEM) of OT1 antigen-specific islets (OVA^+^) compared with bystander CFP islets in nonadjacent positions, after CD8^+^ OT1 T~eff~ cells transfer. (C) Changes in relative mass (volume; mean ± SEM) of bystander islet grafts conjoined with the specific islet graft or separated from the specific islet graft in the same ACE. Bars, 100 µm. \*\*, P \< 0.01; \*\*\*, P \< 0.001. See [Videos 2 and 3](http://www.jem.org/cgi/content/full/jem.20130785/DC1){#supp4} for 3D islet mass visualization before and after CD8^+^ T~eff~ cell--mediated damage to the specific OVA^+^ tissue.](JEM_20130785_Fig3){#fig3}

Strikingly, the bystander RIP-mOVA^−^CFP^+^ islets conjoined to damaged mOVA^+^CFP^−^ islet grafts grew at the interface of immune destruction within days, rather than being subjected to killing ([Fig. 3 A](#fig3){ref-type="fig"}). Increase of the islet mass lacking the specific antigen required close juxtaposition with the site of antigen-specific immune responses. RIP-mOVA^−^CFP^+^ graft mass remained constant if it was not immediately adjacent (i.e., isolated) to a graft harboring the specific antigen ([Fig. 3, A--C](#fig3){ref-type="fig"}). Importantly, the increased mass of conjoined RIP-mOVA^−^CFP^+^ grafts was not a result of hypertrophy of the β cells, as the nuclear density of the conjoined and isolated islets was unchanged ([Fig. S1](http://www.jem.org/cgi/content/full/jem.20130785/DC1){#supp5}). Moreover, imaging analyses showed preservation of the three-dimensional (3D) structure of these islets ([Videos 2 and 3](http://www.jem.org/cgi/content/full/jem.20130785/DC1){#supp6}), precluding the possibility of imaging artifacts associated with islet flattening over time. Because the CFP expression in these islets is driven by the insulin promoter ([@bib21]) and therefore labels differentiated β cells, this direct observation suggests that β cells can regenerate by replication at the site of immune damage, with an extraordinary potential of doubling in days.

Proliferation of bystander β cells in islet grafts under the kidney capsule
---------------------------------------------------------------------------

To examine β cell replication under inflammatory conditions in a site other than ACE, we performed our experiments using a conventional islet transplantation model. Recapitulating the settings in ACE using islets with or without specific antigens for CD8^+^ OT1 T~eff~ cells, B6 recipient mice were transplanted under the kidney capsule with islets from either wild-type B6 or RIP-mOVA^+^ transgenic donors, or a mixture of the two. The premixed islets from RIP-mOVA^+^ and wild-type B6 donors, or single group controls, were pelleted by centrifugation before transplantation under kidney capsule. The kidney subscapular space, although does not allow noninvasive longitudinal analyses of the same graft tissue at a cellular level, enabled the retrieval of a relatively large number of islet grafts for histological analyses.

After engraftment of islets transplanted under the kidney capsule, the recipient animals were injected with activated CD8^+^ OT1 T~eff~ cells, as in the animals bearing ACE grafts ([Fig. 3](#fig3){ref-type="fig"}). We then administered BrdU to the animals to label proliferating cells. The CD8^+^ T~eff~ cells destroyed the RIP-mOVA^+^ islet grafts. This was confirmed by microscopic examination and insulin-staining of kidney tissue sections at the site of the islet engraftment in animals transplanted with RIP-mOVA^+^ islet alone (unpublished data). Using tissue sections of the islet grafts from the mice receiving B6 islets alone or a mixture of B6 and RIP-mOVA^+^ islets, we conducted immunofluorescence staining to detect BrdU incorporation in the nuclei of proliferating β cells. We found that in the group with the mixed engraftment (RIP-mOVA^+^ and B6 islets) and subsequent destruction of RIP-mOVA^+^ islets by OT1 CD8^+^ T~eff~ cells, there was a substantial increase in the proportion of BrdU^+^ β cells in the remaining B6 islets, compared with the group that was transplanted with B6 islets alone ([Fig. 4](#fig4){ref-type="fig"}).

![**Analyses of islet β cell proliferation by BrdU incorporation.** B6 islets, RIP-mOVA^+^ islets, or a mixture of B6 and RIP-mOVA^+^ islets were transplanted under the kidney capsules of B6 mice. At 7 wk after transplantation, 2 × 10^6^ activated OT1 cells were injected i.v. into the mice. BrdU was administered by i.p injection beginning on day 2 after OT1 T cell transfer. The animals were sacrificed on day 10, and kidney tissue sections were prepared to analyze islet grafts. Tissue sections of islet grafts and surrounding kidney tissues were analyzed by immunostaining with anti-insulin and anti-BrdU antibodies and counterstained for nuclei with DAPI. The RIP-mOVA^+^ islet graft group had a complete destruction of islet grafts, and thus it is not presented. Tissue sections of the B6 islet alone group (A) or B6 and RIP-mOVA^+^ islets mixed engraftment group (B) were compared for insulin^+^ cells with BrdU signals. A serial section of the latter group was also used to show the secondary staining only (C). Inset in B is the zoomed-in image of the highlighted area. The BrdU^+^ Insulin^−^ cells were likely the infiltrating lymphocytes that destroyed the RIP-mOVA^+^ islets in the mixed engraftment group. (D) Data were pooled from 2 experiments with 4 mice, with 36 and 34 islets analyzed in the B6 islet alone engraftment and the mixed engraftment groups, respectively. Each data point represents one islet graft (mean ± SEM). \*\*, P \< 0.01. Bar, 50 µm.](JEM_20130785_Fig4){#fig4}

Although it cannot be determined with absolute certainty in the histological analyses whether one particular B6 islet was once in direct contact with one particular RIP-mOVA^+^ islet after the latter was destroyed, the islets from RIP-mOVA^+^ and wild-type B6 donors were premixed and pelleted before being implanted in the renal subcapsular space. In addition, we counted 34--36 islets in each group. Thus, increased BrdU staining in the B6 islets in the mixed transplant group, compared with that in the B6 islets alone transplant group, represents at a group level the effect of close physical proximity of the bystander B6 islets with the RIP-mOVA^+^ islets before the latter was destroyed by OT1 T~eff~ cells. These results, obtained with a platform distinct from the ACE model, corroborated the notion that β cells lacking specific antigens are not subject to bystander killing or damage but replicate in an inflammatory setting, which is consistent with the observations from the imaging analyses of islet grafts in ACE.

T~reg~ cells interacted with T~eff~ cells through direct cell--cell contact in nonlymphoid target tissue
--------------------------------------------------------------------------------------------------------

Immune effector function at the target tissue is controlled by various mechanisms coordinated by T~reg~ cells ([@bib24]). How exactly T~reg~ cells suppress immune response in vivo is still debated. Initial studies with in vitro transwell culture systems showed that T~reg~ cell suppression was effective only if T~reg~ cells were placed in the same culture chamber with T~eff~ cells and antigen-presenting cells ([@bib54]; [@bib58]). Although subsequent studies showed that T~reg~ cells could inhibit T~eff~ cell activation by modulating antigen-presenting cells ([@bib53]; [@bib35]; [@bib64]), several in vitro studies also demonstrated that both human and murine T~reg~ cells could directly suppress T~eff~ cells independent of antigen-presenting cells ([@bib12]; [@bib34]; [@bib37]; [@bib2]; [@bib18]; [@bib23]). However, ex vivo and in vivo imaging studies in lymph nodes did not detect stable contact between T~reg~ and T~eff~ cells ([@bib31]; [@bib55]). This contradiction between in vitro and in vivo studies has left a doubt about the in vivo relevance of contact-dependent T~reg~ suppression. The in vitro trademark activity of T~reg~ cells remains to be reconciled in vivo.

In this study, we examined the pathophysiological relevance of T~reg~--T~eff~ contact at the effector phase in the target tissue in vivo. We used the NOD.SCID reconstitution model with antigen-specific T~reg~ and T~eff~ cells that are genetically tagged with different fluorescence markers for stable labeling and longitudinal study. Adoptive transfer of T cells to lymphopenic animals is followed by homeostatic proliferation and activation of the transferred T cells to fill empty niches in the lymphoid organs ([@bib52]), which could complicate studies of T cell activation and differentiation. However, lymphopenia-associated activation is likely to have minimal impact on our study, as we focused on T cell biology at the final effector phase in the nonlymphoid target tissue, i.e., during the effector phase after activation and differentiation. The lymphopenic reconstitution model is also necessary to avoid undercounting invisible interactions (see Materials and methods) and to generate meaningful measurement of the interactive behavior among T cell subsets.

Indeed, in the T~reg~ cell--protected grafts, a majority of T~eff~ cells were in direct contact with T~reg~ cells ([Fig. 5 A](#fig5){ref-type="fig"}); they displayed a dynamic and contact-featured choreography. The interaction between the T~reg~ and T~eff~ cells usually persisted for the entire length of the imaging sessions (≥30 min) and was characterized by reduced motility ([Fig. 5, A--E](#fig5){ref-type="fig"}; and [Video 4](http://www.jem.org/cgi/content/full/jem.20130785/DC1){#supp7}). This direct contact between T~reg~ and T~eff~ cells was not due to mere crowdedness; in tissue areas that were only sparsely infiltrated, long-lasting contact between T~reg~ and T~eff~ cells was still evident ([Fig. S2](http://www.jem.org/cgi/content/full/jem.20130785/DC1Fig){#supp8}).

![**Noninvasive intravital visualization of T~reg~--T~eff~ cell contact in target tissue.** (A) Snapshots from representative time-lapse recordings demonstrating stable, long-lasting interaction between CD4^+^ T~reg~--T~eff~ interactions within the islet tissue. The majority of interactions lasted for the entire time of the recordings (≥30 min; see [Video 4](http://www.jem.org/cgi/content/full/jem.20130785/DC1){#supp9}). Absolute (B) and relative (C) interaction time between the CD4^+^BDC2.5 T~eff~ and T~reg~ cells (*n* = 50 cell pairs; mean ± SEM). Relative interaction time is calculated by dividing absolute interaction time with total imaging session length. Of note, many of the interactions were already established at the beginning of imaging; hence, actual interaction times are likely longer than those measured during the in vivo imaging timeframe which is limited by the animals' tolerance of general anesthesia. Data points represent one T~reg~--T~eff~ pair and lines represent the mean ± SEM. The interaction index (D) and velocity (E) of both T~eff~ and T~reg~ cells in a mode of contact interaction or not (*n* = 55--100 cells; mean ± SEM). Data represent three experiments with 6 mice. \*\*\*, P \< 0.001. Bar, 30 µm.](JEM_20130785_Fig5){#fig5}

Contact interaction between T~reg~ and T~eff~ cells with or without CD11c^+^ DCs
--------------------------------------------------------------------------------

T~reg~ cells can dampen the expression of the co-stimulatory molecules CD80 and CD86 on the surface of DCs, and thus inhibit T cell activation ([@bib47]; [@bib64]). Whether the function of T~reg~ cells in the target tissue depends on DCs during the effector phase remains unclear. To examine T~reg~--T~eff~ interaction in the context of DCs in protected target tissues, we injected fluorescence-conjugated anti-CD11c antibodies to visualize DCs, in addition to GFP- and CFP-labeled T~reg~ and T~eff~ cells, respectively ([Fig. 6, A and B](#fig6){ref-type="fig"}). CD11c^+^ DCs could be detected in the islet graft, mostly at the periphery ([Fig. 6 B](#fig6){ref-type="fig"}). Consequently, the majority of T~reg~--T~eff~ cell interactions within the graft occurred in the absence of DCs, and it was also the most abundant among the various types of interactions of T~reg~, T~eff~, and/or CD11c^+^ DCs. Clusters of the three types of cells, T~reg~--T~eff~--DC, could be detected but at a much lower frequency than that of T~reg~--T~eff~ cell interaction without DCs. T~eff~--DC or T~reg~--DC interactions could be found at minor frequencies ([Fig. 6 C](#fig6){ref-type="fig"}). The interactions between T~reg~--T~eff~ cells were also stable, with or without CD11c^+^ DCs ([Fig. 6, D and E](#fig6){ref-type="fig"}). The interactions between CD11c^+^ cells and T~eff~ or T~reg~ cells, although occurring in only a minor proportion of the T cells, were also mainly long lasting, with T~reg~--CD11c^+^ cells interactions being somewhat less stable ([Fig. 6, D and E](#fig6){ref-type="fig"}). Overall, these results show that direct contact--based interactions between T~reg~ and T~eff~ cells persisted with or without CD11c^+^ DCs, which could reflect distinct subsets of T cells or distinct stages of the T cell function in the target tissues. The functional relevance of the different types of interactions has already been documented in vitro ([@bib54]; [@bib58]; [@bib12]; [@bib34]; [@bib37]; [@bib2]; [@bib53]; [@bib35]; [@bib64]; [@bib18]; [@bib23]). Our noninvasive in vivo imaging studies shows that those direct interactions do exist in vivo in target tissue. Further studies are needed to determine which interactions are most relevant in what settings for which types of functions.

![**Stable T~reg~--T~eff~ cell interaction with or without CD11c^+^ DCs.** (A and B) Alexa Fluor 647--labeled anti-CD11c antibodies or isotype controls were injected into ACE to visualize DCs at the site of T~reg~--T~eff~ cell interaction in islet grafts. (C) The total count for each type of the interactions was calculated from the images in this experiment (mean ± SEM). (D) The interaction times of the different subsets in time-lapse recordings. (E) The relative interaction time is calculated by dividing absolute interaction time with total imaging session length. The data were pooled from 6 videos from three experiments with 5 mice. \*, P \< 0.05; \*\*\*, P \< 0.001. Bar, 100 µm.](JEM_20130785_Fig6){#fig6}

T~reg~ cells persistently interacted with T~eff~ cells even when outnumbered by T~eff~ cells in damaged target tissues
----------------------------------------------------------------------------------------------------------------------

Next, we examined the behavior of T~reg~ cells in a setting of failed immune regulation. We found that most T~reg~ cells at the site of extensive tissue damage were still persistently interacting with T~eff~ cells, with durations (interaction time) comparable to those in the protected tissues ([Fig. 7, A and B](#fig7){ref-type="fig"}). However, T~reg~ cells were largely outnumbered by T~eff~ cells; as a result, most T~eff~ cells were without T~reg~ cell interactions ([Fig. 7, C and D](#fig7){ref-type="fig"}). Thus, regardless of success or failure in protecting the target tissue, T~reg~ cells persistently interacted with T~eff~ cells, but an imbalance in the numbers of T~reg~ versus T~eff~ cells characterized the outcome, i.e., immune damage versus protection.

![**T~reg~ cells persistently interacted with T~eff~ cells in damaged tissue, despite an imbalance in T~reg~ versus T~eff~ numbers.** CD4^+^ T cell behavior was analyzed in the graft tissue that was being destroyed due to failed immune regulation or protected by successful T~reg~ cell regulation. Protected islet grafts had at least 80% of original islet mass, whereas damaged islet graft had 20% or less. (A) Representative fluorescence micrographs (3D rendering) showing protected (left) and damaged (right) islet grafts (gray; visualized by laser backscatter) in NOD.SCID mice reconstituted with GFP-labeled CD4^+^ BDC2.5 T~reg~ cells and CFP-labeled CD4^+^ BDC2.5 T~eff~ cells. (B) T~reg~--T~eff~ interaction time in protected versus damaged grafts (mean ± SEM). (C) Ratios of T~reg~--T~eff~ cell pairs within protected versus damaged grafts. The T~reg~--T~eff~ cell pairs outside of the target graft tissue, in the iris in the same ACE, were analyzed as controls for the target tissue (mean ± SEM). (D) Interaction index (ratio of T~eff~ cells with or without T~reg~ interactions during the entire imaging sessions) in protected *vs.* damaged grafts (mean ± SEM). Imaging experiments in A--D were done on days 18--25 after T cell transfer. (E--G) T~eff~ and T~reg~ cell numbers in the target tissue at the initial phase of T cell infiltration (days 10--12, all animals were free of diabetes) and a later stage (days 17--20) when some animals developed diabetes with near complete (\>80%) damage of the islets and some animals were protected, even though they received the same kind of T~eff~ and T~reg~ cell mixture in the same experiment. T~eff~ (E) and T~reg~ (F) cell numbers and T~reg~/T~eff~ ratios (G) in the target tissue were analyzed in the same graft before and after extensive damage occurred (if it occurred). Results represent 3 experiments in a total of 4--6 mice in each group (the protected vs. damaged groups). Each data point represents one islet. Unpaired Student's *t* tests were performed in B and D and one-way ANOVAs with Tukey's post-hoc analyses were performed in C and E--G; \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. Bar, 50 µm.](JEM_20130785_Fig7){#fig7}

The imbalance of T~eff~ versus T~reg~ cells in the target tissue developed in some animals but not others even though they were injected with the same type of T~reg~ and T~eff~ cell mixture in the same batch of experiments. We studied the kinetics of the imbalance, taking advantage of our noninvasive platform to image both T~reg~ and T~eff~ cell populations in the same islet grafts longitudinally. The grafts were analyzed at two time points: days 10--12, when all animals were free of diabetes but had an onset of infiltration of both T~reg~ and T~eff~ cells (without substantial damage of the grafts); and days 17--20 when some animals suffered from new-onset diabetes (the islet damaged group) but other remains diabetes-free (the islet protected group). Of note, if an animal was still free of diabetes at this time point, it would remain protected for a long term, as shown in [Fig. 1](#fig1){ref-type="fig"}.

At the time point of days 10--12, the islets that would be damaged later and the islets that remain protected for a long term did not have significant difference in T~eff~ cell infiltrates ([Fig. 7 E](#fig7){ref-type="fig"}). The difference lays in the T~reg~ cells. The first group, at this predamage stage, had significantly lower numbers of T~reg~ cells compared with the protected group ([Fig. 7 F](#fig7){ref-type="fig"}). As a result, the T~reg~/T~eff~ cell ratio was significantly reduced at this predamage time point in the would-be damaged group versus the would-be protected group ([Fig. 7 G](#fig7){ref-type="fig"}). It was only at the time point of day 17--20, when the damaged group had extensive destruction of the tissue, that the grafts had significantly more T~eff~ cells than the protected group ([Fig. 7, E and G](#fig7){ref-type="fig"}). Overall, these data show that the grafts with successful or failed T~reg~ cell protection did not have significant difference in the number of T~eff~ cells at the onset of T cell infiltration in the target tissue. These results suggest that in this experimental setting, the two different immune outcomes (graft protection or damage) are probably not caused by a difference in the numbers of T~eff~ cells expanded during the priming phase. Alternatively, the results highlighted the critical requirement of sufficient recruitment of T~reg~ cells to the inflammatory site and the continuous presence of T~reg~ cells for optimal suppression, as suggested in previous studies with models of autoimmune oophoritis ([@bib43]), islet transplantation ([@bib66]), and other models of immune-mediated ([@bib59]; [@bib48]).

To further examine the behavior of T~reg~ cells in a setting of severe imbalance with T~eff~ cells, we examined the impact of acute removal of T~reg~ cells after establishment of target tissue protection. This approach also tested whether persistent contact with T~reg~ cells might impinge a lasting change of migratory behavior of T~eff~ cells. We used a Foxp3^DTR^ transgenic model, which carries a diphtheria toxin (DT) receptor transgene under the control of Foxp3 promoter, enabling acute depletion of 80--90% of T~reg~ cells with a low dose of DT ([@bib14]). In ACE islet grafts, the T~eff~ cell--mediated islet damage was suppressed by using either Foxp3^DTR+^ T~reg~ cells or Foxp3^DTR−^ T~reg~ controls. After stable protection of the islet grafts by the T~reg~ cells was established, the animals were treated with DT. This treatment led to an acute removal of the T~reg~ cells and a precipitous reduction in the T~reg~/T~eff~ cell ratio in the tissue ([Fig. 8 A](#fig8){ref-type="fig"}). The efficacy of GFP^+^ cell removal in the islet graft indicated that the adoptively transferred GFP^+^ cells maintained Foxp3 expression even at the effector phase in the target tissues. Depletion of T~reg~ cells led to extensive tissue damage ([Fig. 8 B](#fig8){ref-type="fig"}), and increased motility of T~eff~ cells ([Fig. 8, C--E](#fig8){ref-type="fig"}). While the residual T~reg~ cells remained in stable contact with T~eff~ cells, the T~reg~/T~eff~ cell disproportion caused by the T~reg~-cell depletion treatment resulted in most of the T~eff~ cells in the target tissue no longer having T~reg~-cell partners. Thus, intimate T~reg~--T~eff~ interaction did not irreversibly alter the aggressiveness of the T~eff~ cells.

![**Acute removal of T~reg~ cells after T~reg~--T~eff~ interaction establishment altered T~eff~ cell motility but residual T~reg~ cells maintained contact with T~eff~ cells.** NOD.SCID mice with islet grafts established at the ACE site were injected with CD4^+^ BDC2.5 T~eff~ cells, together with CD4^+^ BDC2.5 T~reg~ cells (blue) with or without the diphtheria toxin receptor (green) at a ratio of 1:1. After establishment of protection, all mice were injected with diphtheria toxin (50 ng/g body tissue). (A and B) The effect of acute T~reg~ cell depletion (with an efficacy of ∼80--90%) on T~reg~/T~eff~ ratio (A) and tissue damage (B) after acute T~reg~ depletion (mean ± SEM). (C) The effect of T~reg~ cell removal on T~eff~ cell motility (physical displacement, flower plot of individual cell tracks), to test if T~eff~ cells exhibit altered motility after disengagement from T~reg~ cells. (D) T~eff~ cell displacement rate (µm/min; mean ± SEM). (E) The average T~reg~--T~eff~ interaction time after acute removal of the majority of the T~reg~ cells by diphtheria toxin treatment (mean ± SEM). Data represent four mice per group from two experiments. It should be noted that the intravital imaging platform enabled us to perform noninvasive imaging at the same tissue spot in the same animal longitudinally, so the pretreatment measurements (day 0) also serve as internal controls for posttreatment measurements within each group. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20130785R_Fig8){#fig8}

A role of CTLA4 in T~reg~--T~eff~ cell interaction, likely through motility regulation
--------------------------------------------------------------------------------------

The function of T~reg~ cells depends on CTLA4 ([@bib64]), which also regulates T~eff~ cell function ([@bib57]). We tested here the role of CTLA4 in maintaining T~reg~--T~eff~ cell interaction by administering anti-CTLA4-antibody blockade after stable T~reg~--T~eff~ cell interactions and T~reg~-cell protection were established. The anti-CTLA4 treatment under this condition did not cause diabetes (data not shown). It increased T~eff~ cell numbers in the target tissue, more so than in T~reg~ cell numbers ([Fig. 9, A and B](#fig9){ref-type="fig"}), and resulted in decreased T~reg~/T~eff~ ratios ([Fig. 9, C](#fig9){ref-type="fig"}). The treatment did not immediately disrupt the interaction between the CD4^+^ T~reg~--T~eff~ pairs. However, the proportion of interacting T~reg~--T~eff~ pairs declined over time after CTLA4 blockade ([Fig. 9, D](#fig9){ref-type="fig"}), and their interaction time was shortened ([Fig. 9, E and F](#fig9){ref-type="fig"}). Although CTLA4 blockade led to increased motility of CD4^+^ BDC2.5 T~eff~ and T~reg~ cells in T~reg~ cell--protected grafts, it decreased the motility of CD8^+^ OT1 T~eff~ cells. Moreover, in a model wherein CTLA4 in CD8^+^ OT1 T~eff~ cells were modulated with RNAi ([@bib8]; [@bib32]), CTLA4 reduction decreased motility of T~eff~ cells, suggesting an intrinsic effect of CTLA4 in T~eff~ cell motility ([Fig. 10](#fig10){ref-type="fig"} and [Videos 5 and 6](http://www.jem.org/cgi/content/full/jem.20130785/DC1){#supp10}). Collectively, these results suggest that CTLA4 might influence T~reg~--T~eff~ interaction through motility regulation, but the exact effect depends on the nature of the immune settings and cell types.

![**The effect of CTLA4 modulation on T~reg~--T~eff~ cell interaction.** NOD.SCID mice carrying islet grafts in ACE were injected with CD4^+^ BDC2.5 T~eff~ and T~reg~ cell mixture. After T~reg~ cell protection in the tissue was established (∼30 d after T cell transfer), mice were treated with either PBS control or anti-CTLA4 monoclonal antibody (20 µg/g body weight, *n* = 3 different mice in each group). Notably, the intravital imaging platform enabled us to noninvasively image the same tissue spot in the same animal longitudinally, as in these experiments and throughout the study. Therefore, the pretreatment measurements also serve as internal controls for posttreatment measurements. (A) T~eff~ cell numbers and (B) T~reg~ cells numbers in the target tissues (mean ± SEM). (C) Intra-islet graft T~reg~/T~eff~ cell ratio over time after anti-CTLA4 antibody blockade (*n* = 10--11 islet grafts per group per time points; mean ± SEM). (D) Interaction index, calculated as the ratio of T~eff~ cells with or without T~reg~ cell interaction, after anti-CTLA4 or control treatment (mean ± SEM). Arrows in A--D indicated injection of anti-CTLA4 antibodies. (E and F) The duration of T~reg~--T~eff~ cell interactions after CTLA4 blockade, in actual imaging time (E) and relative to the length of whole imaging session (F; *n* = 24--40 cell pairs; mean ± SEM). One-way ANOVA across all time points in all groups did not yield statistical significance, likely because of the large variations among individual animals and time points in each group in these longitudinal imaging experiments with live animals; however, there was significant difference among pretreatment controls and posttreatment measurements within the anti-CTLA4 treatment group. \*, P \< 0.05, one way ANOVA was performed with a Tukey's multiple comparison's post-hoc analyses, compared with both pretreatment measurement of the same animal or control-treated animals. \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20130785_Fig9){#fig9}

![**The effect of CTLA4 on T cell motility may depend on the type of T cells and their settings.** (A) The velocity of CD8^+^ OT1 T~eff~ cells (*n* = 3 mice, 40 cells, mean ± SEM) in ACE islet grafts in B6 mice is compared with that of CD4^+^ BDC2.5 T cells in ACE islet grafts in NOD.SCID mice. For CD4^+^ BDC2.5 T cell analyses, the CD4^+^ T~eff~ cells (*n* = 5 mice, 110 cells; mean ± SEM) and CD4^+^ BDC2.5 T~reg~ cells (*n* = 5 mice, 101 cells, mean ± SEM) were from animals injected either with T~eff~ and T~reg~ cell mixture (the second and third groups) or from CD4^+^ BDC2.5 T~eff~ cells only (fourth group, *n* = 3 mice and 107 cells). Each dot represents one cell and the lines in plots represent mean ± SEM. (B and C) Transient change of intra-graft CD4^+^ BDC2.5 T cell velocities after anti-CTLA4 treatment (*n* = 30--90 cells per group for each time point; mean ± SEM). (D and E) The effect of CTLA4 modulation on displacement (D) and velocity (E), respectively, on intra-graft CD8^+^ OT1 T~eff~ cells. Animals were treated with anti-CTLA4 antibodies (*n* = 3 mice) or PBS or hamster Ig control (*n* = 4 mice), or they carried a CTLA4 RNAi transgene (*n* = 3 mice). Data represent two experiments and are from analyses of 40 cells (mean ± SEM) in each group. Each dot in E represents one cell. \*\*, P \< 0.01; \*\*\*, P \< 0.001. See [Videos 5 and 6](http://www.jem.org/cgi/content/full/jem.20130785/DC1){#supp11}.](JEM_20130785R_Fig10){#fig10}

DISCUSSION
==========

Control of immune damage at the effector phase is a crucial and perhaps the most realistic therapeutic target in clinical intervention of immune-mediated diseases ([@bib6]). Improvement of therapeutic interventions will require in-depth understanding of the immune cell behavior in target tissues and of the reaction of target tissue cells in response to insult. The current study suggests that the contact-dependent mode of immune cell interaction in the target tissue is a critical part of pathophysiology at the effector phase of immune responses, and immune tolerance induction may be facilitated by promoting intimacy between pathogenic and protective immune cells. In this regard, it is highly relevant that tissue antigen-specificity, as opposed to bystander killing ([@bib60]), shapes tissue fate in the effector phase.

With the tools currently available for longitudinal imaging of antigen-specific T cells in target tissues, we uncovered some basic behaviors of different lineages of T cells during the effector phase. CD8^+^ T cells are well known for contact-dependent killing. CD4^+^ T cells, on the other hand, are better known as various helper subsets, although increasing attention has been put on their potential cytotoxicity function. Although our current models do not allow us to compare the biology of CD4^+^ and CD8^+^ T cells in an ideally analogous setting, our studies provide in vivo evidence for contact-based killing of target cells by both. The observation adds to efforts to understand the behaviors of these two distinct lineages of T cells at various stages of their activation, differentiation and functioning ([@bib29]). Our results, however, do not exclude indirect mechanisms of target killing by CD4^+^ T~eff~ cells, and development of new tools should enable further studies to investigate such mechanisms in vivo.

It is important to make the distinction between our findings of stable T~reg~--T~eff~ contact interaction in target tissue and those in previous reports on lack of direct T~reg~--T~eff~ contact in lymph nodes ([@bib31]; [@bib55]). T~reg~ cells play a major role in peripheral immune tolerance, likely through a variety of mechanisms ([@bib59]; [@bib48]; [@bib24]). However, key features of T~reg~ cell biology in vivo remain to be clarified, including whether T~reg~ cells interact with T~eff~ cells through direct contact. Two groups independently reported that T~reg~ cells could not suppress in vitro proliferation responses of T~eff~ cells if they were placed in a different chamber in a trans-well culture system ([@bib54]; [@bib58]). Although this could be attributed to an effect of T~reg~ cells on antigen-presenting cells ([@bib53]; [@bib35]; [@bib64]), robust evidence has also been presented for direct suppression T~eff~ cells by T~reg~ cells independent of antigen-presenting cells ([@bib12]; [@bib34]; [@bib37]; [@bib2]; [@bib18]; [@bib23]), such that contact-dependent suppression has been regarded as an in vitro trademark of T~reg~ cell activity ([@bib46]). On the other hand, imaging analyses of explanted lymph nodes in an autoimmune diabetes animal model did not detect stable interaction between CD4^+^ BDC2.5 T~eff~ cells and T~reg~ cells, but detected interaction between T~reg~ cell and DCs, suggesting a role of T~reg~ cells in the priming phase of T~eff~ cells ([@bib55]). The suppressive effect of T~reg~ cells in the priming phase has also been documented with the findings from other studies ([@bib59]; [@bib48]). Absence of stable T~eff~--T~reg~ cell contact in draining lymph nodes was also reported independently by another group using a different model system ([@bib31]).

In contrast, our in vivo studies focused on the effector phase in the nonlymphoid target tissue. We found that T~reg~ cells persistently interacted with T~eff~ cells through direct cell--cell contact. Importantly, the contact-based interactions between T~reg~ and T~eff~ cells in the target tissues were observed both in the presence and in the absence CD11c^+^ DCs, although more often for the latter. In this regard, it should be noted that a previous study ([@bib55]) showed that, in draining lymph nodes, although both T~eff~ cells and T~reg~ cells had stable interactions with DCs, such interactions did not lead to stable T~reg~--T~eff~ contact. Therefore, a platform of antigen-presenting cells does not obligate direct T~reg~--T~eff~ cell interaction. In addition, recent evidence also suggested that niche-filling homeostasis of T~reg~ cells may occur independently of DCs ([@bib38]). Nevertheless, our observations do not deemphasize the role of DCs in initiation and progression of immune damage. Homeostasis of DCs was shown to play a critical role in autoimmune damage of pancreatic islets ([@bib9]). In the standard NOD model of autoimmune diabetes, as well as in the BDC2.5 TCR-transgenic model, the role of DCs in initiating autoimmune diseases and their potential in tolerogenic therapies have been clearly demonstrated ([@bib62]; [@bib56]; [@bib33]; [@bib11]; [@bib61]). We believe that the visual evidence of direct T~reg~--T~eff~ interaction in target tissue in vivo, with or without the involvement of CD11c^+^ DCs, reconciles the discrepancy between in vitro and in vivo observations on a basic aspect of T~reg~ cell biology.

The molecular basis of T~reg~--T~eff~ cell direct engagement remains to be elucidated. A previous study ([@bib36]) reported that CD80/CD86-deficient T~eff~ cells were resistant to T~reg~ cell suppression. We explored along this line but did not detect expression of CD80 or CD86 on T~reg~ cells or T~eff~ cells in the target tissues by cytolableing in situ with specific antibodies, nor did we find a disruptive effect on T~reg~--T~eff~ cell interaction after injecting anti-CD80 or anti-CD86 antibodies directly into ACE (unpublished data). However, our observation in this regard is preliminary in scope and limited to the target tissue, and thus does not invalidate the hypothesis that CTLA4 expressed by T~reg~ cells may bind to CD80/CD86 on T~eff~ cells to facilitate direct cellular interactions ([@bib36]). On the other hand, the data from our studies suggest that CTLA4 might affect T~reg~--T~eff~ cell interaction through other mechanisms. A study with a conditional knockout of CTLA4 showed that T~reg~ cells require CTLA4 for functioning in vivo ([@bib64]). We showed here that CTLA4 played a role in regulating T~reg~--T~eff~ cell interaction in target tissue. This role may be related to motility regulation of both T~reg~ and T~eff~ cells. Of note, the role of CTLA4 in T cell motility control has been debated. [@bib44] reported that CTLA4 enhanced the motility of T cells and thus reversed the stop signal originated from engaging the TCR, an effect that may preferentially impact T~eff~ cells over T~reg~ cells ([@bib28]). This evidence suggested that manipulating CTLA4-based motility control could lead to therapeutic advance. Indeed, a recent study found that anti-CTLA4 antibody treatment inhibited CD8^+^ T cell motility and promoted antitumor immunity ([@bib42]). However, another study by [@bib15] showed that anti-CTLA4 treatment did not alter the motility of autoimmune CD4^+^ BDC2.5 T cells in draining lymph nodes. Our imaging analyses of CD4^+^ and CD8^+^ T cells during the effector phase within target tissue indicate that the exact effect of CTLA4 on T cell motility may vary in different T cell subsets and may be influenced by distinct circumstance of cellular interactions.

In our experiments, CTLA4 blockade caused only modest changes on cellular interaction. It did not substantially break tolerance under the conditions we tested. The small effect on T~reg~--T~eff~ cell interaction could be contributed by altered motility controls, although it is still a challenge to determine the cause and effect relationship in such in vivo settings. It remains to be determined how CTLA4 blockade led to an increase in T~eff~ cells, rather than T~reg~ cells, in the target tissue. The resulting imbalance of T~reg~/T~eff~ ratios, however, did not seem likely to account for the changes in durations of T~reg~--T~eff~ cell interactions, as reduced T~reg~/T~eff~ ratios did not lead to reduced T~reg~--T~eff~ interaction time in the other settings of our studies. Although these results suggest novel facets of CTLA4 function beyond the scope of this study ([@bib20]), they may also reconcile the debate on whether CTLA4 controls T cell motility ([@bib44]; [@bib15]). Importantly, in addition to its impact on the TCR stop signals, dysregulation of CTLA4-based motility control may lead to disruption of the T~reg~--T~eff~ cell interaction time in target tissues, which may in turn lead to exacerbated tissue damage.

Our longitudinal and noninvasive observation of live tissue in animals documented growth of healthy tissue that avoided immune cell recognition. For most target tissue cells, unlike immune cells, motility is not typically in their nature. However, they may not be mere sitting ducks in a setting of immune destruction. Rather, they may be capable of a resilient response at the inflammatory front, as illustrated by the dramatic growth of the β cells in bystander islets that were not recognized by antigen-specific T~eff~ cells. The insulin-producing β cells can regenerate through various mechanisms, which is another topic of debate. Notably, an association between microenvironment inflammation and increased β cell proliferation was recognized during insulitis and pancreatitis ([@bib45]; [@bib5]; [@bib13]). A mode of β cell regeneration through replication was demonstrated in animal models, but it was evident only after months of follow up ([@bib10]). A recent study ([@bib65]) showed that fast replication of pancreatic β cells could be induced by treatment with an antagonist compound of insulin receptors that stimulate production of betatrophin. The intravital evidence from our study is consistent with the notion that β cells can regenerate in vivo by replication from differentiated cells, yet with a surprising rate of doubling in mass within days. The fast regeneration could be contributed to by inflammatory signals released at the interface of immune damage. Future studies are needed to uncover the molecular signals and contextual cues that led to this surprising potential of β-cell growth under antigenic incognito. These studies may ultimately aid tissue regenerative therapies in type 1 diabetes and other disorders caused by immune damage.

MATERIALS AND METHODS
=====================

### Mouse models.

Lines of transgenic mouse models were crossed or backcrossed to generate the necessary combinations of specific T cells and target tissue with distinct fluorescence reporters. Detailed descriptions of their genetic makeup, antigen-specificity, and fluorescence properties were provided in Table S1. NOD.BDC2.5 ([@bib25]), NOD.Foxp3^DTR^ ([@bib14]), NOD.CTLA4 shRNA (CTLA4KD7; [@bib8]), NOD.PL4 ([@bib8]), OT1 ([@bib22]), RIP-mOVA ([@bib26]), MIP-CFP ([@bib21]) and CAG-CFP ([@bib17]) transgenic lines were described previously. The CTLA4shRNA and PL4 lines were backcrossed onto B6 background for \>10 generations ([@bib32]). The CTLA4shRNA transgene caused 2--3-fold reduction in CTLA4 expression. The stability of the RNAi effect in the transgenic lines on different genetic background has been established ([@bib8]; [@bib32]). FIR (Foxp3-IRIS-RFP knock-in) mice ([@bib63]) were backcrossed onto the NOD background for 10 generation to create the NOD.Foxp3^FIR^ line. CAG-CFP, obtained on the C57BL/6 background, were backcrossed onto the NOD genetic background for 10 generations, and crossed with NOD.BDC2.5 and NOD.Foxp3^FIR^. All animals were maintained in a specific pathogen--free barrier facility at the University of Miami, and the studies are approved by the Institutional Animal Care and Use Committee at the University of Miami.

### Cell sorting and adoptive transfer.

Antigen-specific CD4^+^ BDC2.5 T~eff~ and T~reg~ cells were purified from transgenic mice on the NOD genetic background that carries the BDC2.5 transgene and the Foxp3^FIR^ knock-in alleles, in combination with either the PL4 transgene for a GFP reporter or the CAG.CFP transgene for a CFP reporter. Flow cytometry staining of spleen and lymph node cells was conducted according to a standard procedure ([@bib27]). T~eff~ and T~reg~ cells were sorted by using a FACSAria II flow cytometer (BD), using the following parameters: CD4^+^CD25^−^CFP (or GFP) ^+^BDC2.5^+^CD62L^+^Foxp3^FIR−^ for T~eff~ cells, and CD4^+^CD25^+^GFP^+^BDC2.5^+^Foxp3^FIR+^ for T~reg~ cells. The RFP expressed by the Foxp3^FIR^ allele is used as a specific lineage marker for flow cytometry purification of T~reg~ cells, but RFP signal is not strong enough for a reliable tracking of live cells in animals. Therefore we used an additional, nonlineage-specific GFP marker to track the cells in animals after the purified GFP^+^Foxp3^RFP+^ cells were transferred. To enable punctuated, acute removal/depletion of Foxp3^+^ T~reg~ cells after T~reg~-cell protection is established, an additional transgene, Foxp3^DTR^, the diphtheria toxin receptor (DTR) driven by a Foxp3 promoter, is crossed with NOD.BDC2.5.Foxp3^FIR^.PL4 transgenic mice, to generate NOD.BDC2.5.Foxp3^FIR^.PL4.Foxp3^DTR+^ mice or NOD.BDC2.5.Foxp3^FIR^.PL4.Foxp3^DTR−^ controls. From these mice, Foxp3^DTR+^ and Foxp3^DTR−^ T~reg~ cells, respectively, were purified with CD4^+^GFP^+^BDC2.5^+^Foxp3^FIR+^CD25^+^ markers, for adoptive transfer. Purified T~eff~ cells, or a mixture of purified T~eff~ and T~reg~ cells were injected intravenously into NOD.SCID mice, at doses of 5--10 × 10^4^ cells with T~eff~--T~reg~ ratios at 1:1. Some of the recipients had stable islet grafts established in ACE. In animals bearing islet grafts in ACE, the cervical lymph nodes draining the eyes likely play an important role in activation and differentiation of the antigen-specific T cells. The lymphopenia reconstitution model was necessary for our study, due to current limitations in tools for long-term, simultaneous tracking of different lineages of T cell in vivo. If one uses an immunocompetent animal as a recipient, rather than reconstitute a lymphopenic animal with highly purified, fluorescence-tagged T cell players, an invisible T~reg~ cell from host could be interacting with a fluorescence-tagged T~eff~ cell, but we would have to count that T~eff~ cell as if it had no T~reg~ cell interaction. That would prevent us from making meaningful conclusions on the extent of T~reg~ and T~eff~ cell interaction. Flow cytometry analyses of the recipient mice were performed to verify the stability of Foxp3 expression of the adoptive transferred T~reg~ cells ∼3 wk later, using the Foxp3-IRES-RFP reporter ([@bib63]).

Antigen-specific CD8^+^ T~eff~ cells were purified from transgenic mice on the C57BL/6 background carrying the OT1 transgene and the Foxp3^FIR^ knock-in allele, in combination with the PL4 transgene for a GFP reporter, or CTLA4shRNA/PL4 transgene for a GFP reporter and CTLA4shRNA for CTLA4 RNAi knockdown. Splenocytes from the mice were stimulated with the OT1 specific ovalbumin peptide (SIINFEKL) for 24 h. CD8^+^ T~eff~ cells were purified (\>95% purity) with magnetic-bead-based cell sorting, and injected intravenously into B6 mice bearing islet grafts in ACE or under the kidney capsules.

### CTLA4 blockade and acute depletion of T~reg~ cells.

To examine the molecular role of CTLA4 in maintaining T~reg~--T~eff~ cell interaction, anti-CTLA4 antibody (clone UC10-4F10-11) were injected intraperitoneally into mice, at 40 µg/g body weight, two consecutive doses at 3 d apart, after T~reg~ cell established graft protection and stable T~reg~--T~eff~ cell interaction in the graft were detectable (typically \>15 d after T cell transfer). This monoclonal antibody blocks CTLA4 function without depleting T~reg~ cells ([@bib39]). To test the effect of CTLA4 blockade on CD8^+^ T~eff~ cells, one dose of anti-CTLA4 antibody was used at the time of OT1 T cell transfer into the animals. For punctual removal of diphtheria-toxin-receptor--tagged T~reg~ cells, mice carrying DTR^+^ T~reg~ cells or control DTR^−^ T~reg~ cells were injected (50 ng/g body weight) with DT at a schedule of day 0, 1, and 3, similar to a previously described regimen ([@bib14]), after graft protection was established and stable T~reg~--T~eff~ interactions were detected.

### Intraocular injection of fluorescence-tagged antibodies for in situ cytolabeling.

In some instances, fluorescently conjugated antibodies were injected directly into ACE for in vivo cytolabeling in situ. With our intravital imaging platform, the injected antibodies can effectively label cells up to 50 µm deep within the graft tissue, which is at the similar depth capacity for accurately tracking cells marked with genetic tags of fluorescence markers ([@bib1]). After mice were adoptively transferred with T~reg~ and T~eff~ cells, mice were injected with fluorochrome-conjugated antibodies directly into the anterior chamber. All antibodies were tested with isotype controls to determine specificity of the in situ labeling. The following is a list of the antibodies and their isotype controls. BV605 conjugated anti-CD11b monoclonal antibody or rat Ig2a isotype control; Alexa Fluor 647--conjugated anti-CD11c, anti-CD80, and anti-CD86 monoclonal antibodies and hamster IgG isotype control (BioLegend). APC-conjugated Annexin V (eBioscience) was used to assess apoptotic cells in ACE grafts. This in vivo assay for β cell apoptosis was described previously ([@bib49],[@bib50]).

### Islet transplantation into ACE and noninvasive in vivo imaging.

The pancreatic islets were transplanted into ACE by injection through the cornea, as previously described ([@bib1]; [@bib49],[@bib50]). The cornea serves as a natural window for noninvasive visualization of transplants. This injection procedure does not entail substantial injury to the cornea or the eye chamber. At least 2 wk were allowed for complete engraftment of the islets before any experimentation. Intravital imaging of the transplants was conducted by confocal microscopy, with a Leica upright TCS SP-5broadband confocal microscope (using Leica 20X/0.5NA HCX APO L U-V-I 12 lens for PBS immersion), as previously described (2008a,b; [@bib1]). T~reg~ and T~eff~ cells were visualized by GFP or CFP fluorescence. Target islet cells were visualized by laser backscatter (reflection) or CFP fluorescence 3D (xyz) or time-lapse (xyzt; 4D) noninvasive in vivo imaging was acquired longitudinally. In time-lapse recordings, z stacks were acquired every 2 min for 30--75 min and the z-spacing ranged from 5--7 µm. A key strength of this intravital imaging platform is noninvasiveness that few other intravital cellular imaging platforms have been afforded. This strength not only avoids inadvertent inflammatory signals caused by surgical exposure for imaging needs, but enables us to monitor the same tissue in the same animal longitudinally at cellular resolution. A baseline measurement serves as a rigorous, internal control for all postintervention measurements of the same live tissue in the same live animal.

Animals were routinely monitored by urine and blood glucose levels. Animals transplanted with islet grafts in ACE were examined 2 wk after transplantation for engraftment. After T cell transfer, the islet grafts in ACE were examined every 2--3 d with the imaging microscope. Animals with two consecutive readings of BG \> 250 mg/deciliter were considered diabetic. With regard to individual islet grafts in ACE in setting of immune responses, a graft maintaining \>80% of its original mass was considered protected, and a graft with \<20% of its original mass was considered damaged or failure in immune regulation. In experiments in which a relatively small number of islets were transplanted in ACE, the islet grafts served as indicators of immune responses and the endogenous pancreatic islets maintained blood glucose homeostasis of the animals. The immune damage of islet grafts in ACE always correlated with incidence of diabetes that was caused by immune destruction of endogenous pancreatic islets.

### Islet transplantation in renal subcapsular space and BrdU labeling of proliferating cells.

The responses of bystander islet cells in an inflammatory setting were also examined at a transplantation site that is different from ACE, the renal subcapsular space, which is the standard transplantation site for experimental studies of islet grafts in rodent recipients. It has been an invaluable research tool for decades ([@bib40]). It allows transplantation of islets in a well-confined location that can then be retrieved for histopathological or molecular analyses of a relatively large number of islets. Islets were transplanted under the kidney capsule of B6 mice by the Diabetes Research Institute Preclinical Cell Processing and Translational Models Core facility following standard procedures ([@bib4]; [@bib13]). In brief, pancreatic islets were isolated from either wild-type B6 or RIP-mOVA^+^ transgenic donors. B6 islets, RIP-mOVA^+^ islets, or a mixture of B6 islets and RIP-mOVA^+^ islets were prepared into individual aliquots for each transplant recipient. They were then handpicked with a Hamilton syringe and transferred into a polyethylene tube (PE50; BD; inside diameter 0.58 mm; outside diameter, 0.965 mm) that was kinked at one end, and then pelleted in the kinked tubing by centrifugation at 1,000 rpm for 2 min, to pack them together. The pelleting step was done before the transplantation procedure.

After induction of general anesthesia (isoflurane 2%/oxygen mix, to effect), a left flank incision was performed and the left kidney exteriorized and exposed. Under a dissection microscope and using microsurgical forceps, a small breach was performed on the capsule at the caudal pole of the kidney through which the tubing containing the pelleted islets was gently inserted and pushed toward the opposite (cranial) pole. Islets were gently released in the renal subcapsular space under visual microscopic inspection. Next, the tubing was gently removed and the breach on the capsule cauterized to prevent back flow. The kidney was repositioned in the abdominal cavity, and the muscular and cutaneous layer sutured. The graft-bearing mice were rested for ∼7 wk after transplantation to ensure engraftment, and then adoptively transferred with activated OT1 CD8^+^ T cells by intravenous injection. 2 d later, BrdU was injected at a concentration of 10mg/kg every 12 h. On day 10, kidneys were removed, fixed in 4% PFA overnight, followed by immersing in 30% sucrose overnight, and then embedded in OCT. Sections were cut and stained for BrdU incorporation with biotinylated antibodies against BrdU, using an in situ BrdU detection kit (BD) designed for histology use. We modified the secondary staining procedure for immunofluorescence staining. Although isotype controls were not included in the kit, we established the specificity of the BrdU staining procedure with spleen tissue sections from animals with or without BrdU injection treatment. To expose BrdU epitopes in the nuclear DNA, a covered plastic coplin (filled with 50 ml of diluted BD Retrievagen buffer) was preheated in a water bath at 95--97°C. After 30 min, the tissue slides were quickly placed into a preheated jar, and incubated for another 30 min. The tissue slides in the closed jar were then removed and left at ambient temperature for one hour. Primary anti-insulin antibodies (polyclonal guinea pig anti-insulin; DAKO; titration, 1:1,000) and the biotinylated anti-BrdU antibodies were incubated overnight with the tissue sections at 4°C, and then washed according to manufacturer's instructions. Secondary staining was done with Alexa Fluor 488--conjugated streptavidin (Life Technologies; titration, 1:500) and Alexa Fluor 647--conjugated donkey anti--guinea pig F(ab)~2~ (Jackson ImmunoResearch Laboratories; titration, 1:500). Sections were counterstained with DAPI and mounted for fluorescence microscopy. Images were acquired with a Leica inverted TCS SP-5 broadband confocal microscope (using Leica 40×/1.25--0.75NA HCX PL APO lens for oil immersion).

### Image analysis.

Image analyses were performed using the Volocity software (version 6; Perkin Elmer) as previously described ([@bib1]). Images were denoised and contrast-enhanced equally for consistent analyses. Quantitative analyses of cellular movement and T~reg~--T~eff~ cell interaction dynamics were performed automatically in the Volocity with user feedback on drift-corrected 3D time-lapse recordings. Drift correction was performed in Volocity based on proprietary algorithms. T cell counting and movement tracking were performed automatically by the software and dynamic parameters (e.g., velocity, displacement) were derived from time-lapse recordings. T~reg~--T~eff~ cell interaction time and interaction index were calculated manually. The interaction time between the T~reg~--T~eff~ cell interacting pairs was calculated manually using the time stamps embedded in each image frame in a time-lapse series. The interaction index is calculated by dividing the number of T~eff~ cells interacting with T~reg~ cells with the number of T~eff~ cells not interacting with T~reg~ cells. β cell (islet) mass was measured by the software, as previously described ([@bib1]), based on volume detected by either laser backscatter or CFP fluorescence.

Annexin V labeling in islet grafts in ACE was quantified with z-stack images that were acquired ∼10--15 min after injection of APC-labeled Annexin V directly into ACE. Using proprietary algorithms in Volocity, we then measured in the 3D images the amount of overlap in the volume the Annexin V--positive stain with either that of β cells (visualized by CFP or backscatter) or CFP/GFP-labeled T~eff~ cells ([@bib41]). Automatic selection, optimized with user feedback, based on fluorescence of Annexin V--positive cells, β cells, and T cells and volume measurements were performed automatically by the software. The overlap (volume) in Annexin V stain with either that of β or T cells was also derived by the software, and was expressed as a fraction of the total volume of the β and T cells in each islet. Similarly, the number of graft-infiltrating T~eff~ cells was automatically measured based on fluorescence intensity ([@bib1]). Islet cell mass was measured using Volocity software as previously described ([@bib1]), based on islet volume detected either by laser backscatter (reflection) or CFP fluorescence. For example, in [Fig. 3](#fig3){ref-type="fig"}, the volume of CFP-labeled β cells was measured based on CFP fluorescence which is in this case restricted to the bystander islets in this case. In brief, a proprietary detection algorithm built into the Volocity software was used to detect CFP signal based on fluorescence intensity. The detection threshold was set with user feedback to restrict the selection to the CFP-labeled β cells. Once the selection was made, the volume was derived automatically by the software. Longitudinal analyses on the same individual islets were performed using the same approach, and numerical values of islet volumes were expressed as means ± SEM at the different time points under the different conditions.

### Statistical analysis.

Unpaired Student's *t* test was used to compare two samples. For multiple group comparisons, one-way ANOVA tests were performed followed up by Tukey's post-hoc multiple comparisons test. P ≤ 0.05 was considered significant. Asterisks indicate significance (\*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001).

### Online supplemental material.

Fig. S1 relates to [Fig. 3](#fig3){ref-type="fig"} and shows digital estimation of cell nuclear density in islet grafts imaged over time in the living animal. Fig. S2 relates to [Fig. 5](#fig5){ref-type="fig"} and shows that the long-lasting contact between T~reg~--T~eff~ in the target tissue occurred even in areas with sparse infiltration of T cells. Table S1 lists the transgenic mouse models genetically tagged with antigen-specific T cell receptor, fluorescence reporters, and lineage markers for the imaging studies. Video 1 (corresponds to [Fig. 1](#fig1){ref-type="fig"}) shows direct interaction between antigen-specific CD4^+^ T~eff~ cells with target β-cells in pancreatic islet grafts in ACE. Videos 2 and 3 (corresponds to [Fig. 3](#fig3){ref-type="fig"}) shows antigen-specific CD8^+^ OT1 T~eff~ cell--mediated destruction of OVA^+^ islets and concomitant growth of juxtaposed bystander OVA^−^ islets. Video 4 (corresponds to [Fig. 5](#fig5){ref-type="fig"}) shows stable long-lasting interaction between T~reg~ and T~eff~ cells in the target tissue. Video 5 and 6 (corresponds to [Fig. 10](#fig10){ref-type="fig"}) shows CTLA4 blockade reduces CD8^+^ T~eff~ cell motility in target tissue. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20130785/DC1>.
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